Photodynamic therapy for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Wormald, Richard ^a   Evans, J ^b   Smeeth, L ^b   Henshaw, K ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NONE

Author keywords

*Photochemotherapy; Glucose therapeutic use ; Macular degeneration complications; *drug therapy ; Photosensitizing agents *therapeutic use ; Porphyrins *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

DICLOFENAC; GLUCOSE; PLACEBO; VERTEPORFIN;

ALLERGIC REACTION; BACKACHE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA EXTRACTION; EMBASE; HUMAN; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PUBLICATION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 43849109291     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002030.pub3     Document Type: Review

References (37)

1. TAP 1999 {published and unpublished data} Rubin GS, Bressler NM, the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation - TAP report no. 4. Retina 2002;22(5):536-44.
2. *Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Archives of Ophthalmology 1999;117(10):1329-45. [MEDLINE: 10532441].
3. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials - TAP report 2. Archives of Ophthalmology 2001;119(2):198-207. [MEDLINE: 11176980].
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no 5. Archives of Ophthalmology 2002;120(10):1307-14. [MEDLINE: 12365909].
5. VIM 2005 {published data only} Visudyne in minimally classic choroidal neovascularisation study group. Verteporfin therapy od subfoveal minimally classic choroidal neovascularization in age-related macular degeneration. Archives of Ophthalmology 2005;123:448-57.
6. VIP 2001 {published data only} Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. American Journal of Ophthalmology 2002;133(1):168-9. [MEDLINE: 11755871].
7. *Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. American Journal of Ophthalmology 2001;131(5):541-60. [MEDLINE: 11336929].
8. Japan 2003 The Japanese Age-Related Macular Degeneration Trial (Jat) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. American Journal of Ophthalmology 2003;136(6):1049- 61.
9. Schmidt-Erfurth 1999 Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, et al.Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration. Results of retreatment in a phase 1 and 2 study. Archives of Ophthalmology 1999;117(9):1177-87. [MEDLINE: 10496389].
10. ADD-V Southeastern Retina Associates. Currently enrolling clinical trials. www.tennesseeretina.com/news (accessed 22 May 2007).
11. VALIO Slakter JS, Rosenfeld PJ. Verteporfin with altered (delayed) light in occult CNV (VALIO) - Results of a phase II controlled clinical trial. Investigative Ophthalmology & Visual Science. 2003; Vol. 44:1101.
12. VER Stur M. Verteporfin Early Retreatment (VER) - 12-month results of a phase IIIb controlled clinical trial. Investigative Ophthalmology & Visual Science. 2004:2275.
13. VIO Retinal Physician. AMD Treatment Choices for Today and Tomorrow. Verteporfin and pegaptanib lead, with a pipeline of new possibilities under investigation. http://www.retinalphysician.com/article.aspx?article=100074 (accessed 22 May 2007).
14. Armbrecht 2004 Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. British Journal of Ophthalmology 2004;88(10):1270-3.
15. Arnold 2004 Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, et al.Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. American Journal of Ophthalmology 2004;137(4): 683-96.
16. Azab 2004 Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, et al.Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 2004;24(1):1-12.
17. Barbazetto 2003 Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, et al.Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Archives of Ophthalmology 2003;121(9):1253-68.
18. Bessler 2004 Bessler NM, VAM Study Writing Committee. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina 2004;24(4): 512-20.
19. Blinder 2003 Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, et al.Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. American Journal of Ophthalmology 2003;136(3):407-18.
20. Borodoker 2002 Borodoker N, Spaide RF, Maranan L, Murray J, Freund KB, Slakter JS, et al.Verteporfin infusion-associated pain. American Journal of Ophthalmology 2002;133(2):211-4.
21. Bressler 2002 Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al.Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Archives of Ophthalmology 2002;120(11): 1443-54.
22. Bressler 2004 Bressler SB, Pieramici DJ, Koester JM, Bressler M. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management - TAP report No. 6. Archives of Ophthalmology 2004;122(3):325-9.
23. Do 2004 Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages after verteporfin therapy. American Journal of Ophthalmology 2004;137(3):558-60.
24. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
25. Higgins 2006 Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
26. Holz 2003 Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110(2):400-5.
27. Hopley 2004 Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. British Journal of Ophthalmology 2004;88(8):982-7.
28. Kaiser 2006 Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: 5-year results of two randomized clincal trials with an open label extension. TAP report No. 8. Graefe's Archive of Clinical and Experimental Ophthalmology 2006;244:1132-42.
29. Meads 2004 Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. British Journal of Ophthalmology 2004;88(2):212-7.
30. Miller 1999 Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, et al.Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Archives of Ophthalmology 1999;117(9):1161-73.
31. MPS 1994 Macular photocoagulation study group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five year results from randomized clinical trials. Archives of Ophthalmology 1994;112(4):500-9.
32. Pieramici 2006 Writing committee for the VIP Study Group. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration. VIP report no. 4. Archives of Ophthalmology 2006;124:660-4.
33. Rubin 2002 Rubin GS, Bressler NM, Treatment of Age Related Macular Degeneration with Photodynamic therapy TAP Study Group. Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina 2002;22(5):536-44.
34. Schmidt-Erfurth 2003 Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003;110(7):1306-14.
35. Schmidt-Erfurth 2004 Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004;111(5):931-9.
36. TAP 2002 Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no 5. Archives of Ophthalmology 2002;120(10):1307-14.
37. Woodburn 2002 Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002;22(4):391-405.